DM
DMN.F Diamyd Medical AB (publ)
- Market cap
- EUR 9.81M
- P/E
- -
- P/B
- 0.47x
- ROE
- -104.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Aug 2026.
Is DMN.F undervalued?
Graham numberThe Graham number of Diamyd Medical AB (publ) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Diamyd Medical AB (publ) fundamental analysis
No fundamental analysis for Diamyd Medical AB (publ) yet.
Diamyd Medical AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Diamyd Medical AB (publ)
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. It develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. The company was formerly known as Diamyd Therap…
Full company profileDiamyd Medical AB (publ) financial statements
Diamyd Medical AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 922K | 726K | 1.57M | 341K | 253K | 454K | 546K | 130K | - | 478K |
| Gross Profit | -818K | -1.38M | -125K | -4.15M | -2.25M | -3.95M | -3.09M | -3.58M | -3.71M | -2.28M |
| Operating Income | -25.5M | -44.0M | -36.6M | 9.74M | -85.9M | -115M | -116M | -147M | -183M | -258M |
| EBITDA | -25.4M | -43.6M | -36.3M | 10.4M | 61.3M | -98.9M | -111M | -141M | -160M | -245M |
| Net Income | -25.6M | -44.0M | -36.6M | 9.71M | 60.0M | -104M | -116M | -152M | -170M | -256M |
| EPS | -0.45 | -0.78 | -0.53 | 0.14 | 0.84 | -1.35 | -1.35 | -1.52 | - | -1.65 |
| Balance Sheet | ||||||||||
| Total Assets | 98.6M | 55.0M | 74.2M | 89.8M | 201M | 237M | 206M | 217M | - | 365M |
| Total Liabilities | 12.0M | 12.0M | 11.4M | 17.3M | 12.2M | 22.1M | 36.4M | 71.1M | 72.6M | 122M |
| Shareholders' Equity | 86.7M | 43.0M | 62.8M | 72.5M | 189M | 214M | 169M | 146M | 280M | 244M |
| Cash & Short-term Investments | 55.7M | 14.1M | 36.7M | 58.4M | 139M | 120M | 128M | 113M | - | 305M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -25.8M | -41.6M | -39.2M | 16.9M | -109M | -93.2M | -95.1M | -129M | - | -195M |
| Capital Expenditure | 347K | 347K | 1.98M | 1.98M | 4.23M | 34.7M | 11.4M | 8.03M | 0.00 | 992K |
| Free Cash Flow | -25.8M | -41.9M | -39.2M | 14.9M | -114M | -128M | -122M | -137M | - | -196M |
| Ratios | ||||||||||
| ROE | -29.5% | -102.2% | -58.3% | 13.4% | 31.7% | -48.3% | -68.5% | -104.1% | -60.6% | -104.9% |
| ROA | -25.9% | -79.9% | -49.3% | 10.8% | 29.8% | -43.8% | -56.4% | -70.0% | - | -70.0% |
| Net Profit Margin | -2,771.7% | -6,054.1% | -2,334.8% | 2,847.2% | 23,733.6% | -22,801.1% | -21,258.8% | -116,807.7% | - | -53,471.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Diamyd Medical AB (publ) dividends
Diamyd Medical AB (publ) has not paid dividends in the last 10 fiscal years.
Who owns Diamyd Medical AB (publ)
- Insiders 14.25%
- Institutions 23.41%
- Public & others 62.34%
- Shares outstanding 151M
- Free float 132M
Diamyd Medical AB (publ) company profile
- Company name
- Diamyd Medical AB (publ)
- Ticker
- DMN.F
- ISIN
- SE0005162880
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 39
- Fiscal year end
- August
- Address
- Kungsgatan 29, Stockholm, Sweden, 111 56
- Phone
- 46 86 61 00 26
- Website
- diamyd.com
About Diamyd Medical AB (publ)
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. It develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. The company was incorporated in 1984 and is headquartered in Stockholm, Sweden.
Diamyd Medical AB (publ) management
5- Mr. Anders Essen-Möller M.Sc.CEO & Director · born 1941
- Mr. Mathias SkalmstadChief Financial Officer · born 1973
- Ms. Martina WidmanChief Operating Officer · born 1981
- Mr. Anton LindqvistChief Scientific Officer · born 1980
- Sofia MayansHead of Manufacturing Site · born 1976